WallStSmart

Equinor ASA ADR (EQNR)vsIDEXX Laboratories Inc (IDXX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Equinor ASA ADR generates 2284% more annual revenue ($105.98B vs $4.45B). IDXX leads profitability with a 24.6% profit margin vs 4.8%. EQNR appears more attractively valued with a PEG of 1.03. IDXX earns a higher WallStSmart Score of 63/100 (C+).

EQNR

Buy

51

out of 100

Grade: C-

Growth: 2.0Profit: 6.5Value: 7.3Quality: 5.5
Piotroski: 3/9Altman Z: 2.32

IDXX

Buy

63

out of 100

Grade: C+

Growth: 6.7Profit: 9.5Value: 2.7Quality: 5.0
Piotroski: 5/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EQNRUndervalued (+47.4%)

Margin of Safety

+47.4%

Fair Value

$54.29

Current Price

$36.69

$17.60 discount

UndervaluedFair: $54.29Overvalued
IDXXSignificantly Overvalued (-41.2%)

Margin of Safety

-41.2%

Fair Value

$459.52

Current Price

$560.11

$100.59 premium

UndervaluedFair: $459.52Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EQNR3 strengths · Avg: 8.3/10
Market CapQuality
$94.78B9/10

Large-cap with strong market position

Operating MarginProfitability
21.4%8/10

Strong operational efficiency at 21.4%

Free Cash FlowQuality
$2.10B8/10

Generating 2.1B in free cash flow

IDXX3 strengths · Avg: 9.7/10
Return on EquityProfitability
72.9%10/10

Every $100 of equity generates 73 in profit

Operating MarginProfitability
31.8%10/10

Strong operational efficiency at 31.8%

Profit MarginProfitability
24.6%9/10

Keeps 25 of every $100 in revenue as profit

Areas to Watch

EQNR4 concerns · Avg: 2.5/10
Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Revenue GrowthGrowth
-5.1%2/10

Revenue declined 5.1%

EPS GrowthGrowth
-27.3%2/10

Earnings declined 27.3%

IDXX3 concerns · Avg: 2.0/10
PEG RatioValuation
4.032/10

Expensive relative to growth rate

P/E RatioValuation
42.0x2/10

Premium valuation, high expectations priced in

Price/BookValuation
27.8x2/10

Trading at 27.8x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : EQNR

The strongest argument for EQNR centers on Market Cap, Operating Margin, Free Cash Flow. PEG of 1.03 suggests the stock is reasonably priced for its growth.

Bull Case : IDXX

The strongest argument for IDXX centers on Return on Equity, Operating Margin, Profit Margin. Profitability is solid with margins at 24.6% and operating margin at 31.8%. Revenue growth of 14.3% demonstrates continued momentum.

Bear Case : EQNR

The primary concerns for EQNR are Profit Margin, Piotroski F-Score, Revenue Growth. Thin 4.8% margins leave little buffer for downturns.

Bear Case : IDXX

The primary concerns for IDXX are PEG Ratio, P/E Ratio, Price/Book. A P/E of 42.0x leaves little room for execution misses.

Key Dynamics to Monitor

EQNR profiles as a value stock while IDXX is a mature play — different risk/reward profiles.

IDXX carries more volatility with a beta of 1.57 — expect wider price swings.

IDXX is growing revenue faster at 14.3% — sustainability is the question.

EQNR generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

IDXX scores higher overall (63/100 vs 51/100), backed by strong 24.6% margins and 14.3% revenue growth. EQNR offers better value entry with a 47.4% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Equinor ASA ADR

ENERGY · OIL & GAS INTEGRATED · USA

Equinor ASA, an energy company, is engaged in the exploration, production, transportation, refining and marketing of petroleum and petroleum products and other forms of energy, as well as other companies in Norway and internationally. The company is headquartered in Stavanger, Norway.

IDEXX Laboratories Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.

Want to dig deeper into these stocks?